by Clinical Neuropsychologist Online | Thursday, September 17, 2026 | Dementia
Abstract Tau pathology is more closely associated with cognitive deterioration than amyloid burden in symptomatic Alzheimer’s disease (AD), yet tau-targeted trials have often interpreted decreases in soluble phosphorylated tau (p-tau) as evidence of therapeutic...
by Clinical Neuropsychologist Online | Thursday, September 17, 2026 | Dementia
Abstract The therapeutic landscape of Alzheimer’s disease (AD) is rapidly evolving with the clinical adoption of anti-amyloid monoclonal antibodies (mAbs) despite an incomplete understanding of disease mechanisms, progression, and heterogeneity. Designing both...
by Clinical Neuropsychologist Online | Thursday, September 17, 2026 | Dementia
Abstract INTRODUCTION Genetic factors contribute to variability in age-related cognitive decline, yet the molecular mechanisms underlying cognitive resilience remain poorly understood. METHODS We performed single-nucleus RNA sequencing on hippocampal tissue from 107...
by Clinical Neuropsychologist Online | Wednesday, September 16, 2026 | Neurorehabilitation
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | September 16, 2026 Neuro-Rehab Previous Page
by Clinical Neuropsychologist Online | Wednesday, September 16, 2026 | Neuropsychology (general)
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | September 16, 2026 Neuro-General Previous Page
